- Nuwellis Inc (NASDAQ:NUWE) announced the peer-reviewed publication of the results from a 10-year, real-world retrospective analysis in patients using the Aquadex FlexFlow System.
- The study included 334 hospitalized acute decompensated heart failure patients with fluid overload.
- The analysis demonstrated significant reductions in heart failure hospitalizations and 30-day hospital readmission rates, and improvements in renal function response using Aquadex ultrafiltration.
- The published study findings included: Patients experienced an overall 81% decrease in heart failure hospitalizations per year;
- Rehospitalizations for patients after receiving UF with Aquadex were 48% less than the national average at 30 days (12.4% vs. 24%);
- 55% of patients achieved sustained weight loss greater than 15 lbs.; and
- All patients had a stable renal function at follow-up.
- Price Action: NUWE shares are up 20.18% at $13.52 on the last check Tuesday.
Exxon Engages In Discussions To Join UN-Led Methane Reporting Agreement: Report
Exxon Mobil Corporation (NYSE: XOM) reportedly plans to join a U.N.-led initiative that would mandate disclosing
